EU expands scope of Amgen’s Xgeva
European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma.
Read More
Tag: Xgeva
Amgen’s Xgeva cleared for multiple myeloma patients
US regulators have expanded the scope of Amgen’s Xgeva to include the prevention of skeletal-related events in patients with multiple myeloma.
Read More
Cancer Vanguard, Amgen develop commissioning toolkit
The Cancer Vanguard and Amgen have developed a simulation modelling tool to show health commissioners and trusts the financial benefits and challenges of delivering breast cancer medicines in a variety of community settings.
Read More
